James Condulis
Stock Analyst at Stifel
(1.80)
# 3,358
Out of 5,129 analysts
9
Total ratings
37.5%
Success rate
6.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Condulis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $44 → $50 | $34.24 | +46.03% | 2 | Dec 16, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $7.5 → $10 | $3.43 | +191.55% | 1 | Dec 5, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Buy | $24 | $12.67 | +89.42% | 1 | Sep 29, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $87 → $96 | $66.80 | +43.71% | 2 | Sep 2, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $74 → $108 | $40.05 | +169.66% | 2 | Mar 28, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Hold | $30 | $30.66 | -2.15% | 1 | Jan 22, 2025 |
NewAmsterdam Pharma Company
Dec 16, 2025
Maintains: Buy
Price Target: $44 → $50
Current: $34.24
Upside: +46.03%
X4 Pharmaceuticals
Dec 5, 2025
Maintains: Buy
Price Target: $7.5 → $10
Current: $3.43
Upside: +191.55%
Aardvark Therapeutics
Sep 29, 2025
Initiates: Buy
Price Target: $24
Current: $12.67
Upside: +89.42%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $87 → $96
Current: $66.80
Upside: +43.71%
Soleno Therapeutics
Mar 28, 2025
Maintains: Buy
Price Target: $74 → $108
Current: $40.05
Upside: +169.66%
Edgewise Therapeutics
Jan 22, 2025
Initiates: Hold
Price Target: $30
Current: $30.66
Upside: -2.15%